{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-181329","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.209673+00:00","generated_at":"2026-05-31T19:00:17.677090+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Soleno grants performance-based RSUs to executives tied to DCCR NDA milestones","bullets":["CEO Anish Bhatnagar receives 850,000 performance-based RSUs; CFO James Mackaness 100,000; SVP Patricia Hirano 85,000.","Vesting: 25% on Aug 1, 2024; 25% on FDA acceptance of DCCR NDA for Prader-Willi syndrome; 50% on FDA approval.","Board increased 2014 Equity Incentive Plan by 2,000,000 shares, approved by 68.6% of votes at June 2024 annual meeting.","Grants aim to bring key employee equity ownership in line with peer group median."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-181329","json":"https://secwatch.observer/filing/0001193125-24-181329.json","markdown":"https://secwatch.observer/filing/0001193125-24-181329.md","text":"https://secwatch.observer/filing/0001193125-24-181329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/0001193125-24-181329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/d839231d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:00:17.677090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}